All
Phase 3 Trial Launches to Assess EGFR Inhibitor for NSCLC Subset
August 4th 2023Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.
FDA Approves Lonsurf Plus Avastin for Metastatic Colorectal Cancer
August 2nd 2023The Food and Drug Administration has approved the combination of Lonsurf and Avastin for patients with metastatic colorectal cancer previously treated with chemotherapies, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.
Weekly Fosaprepitant Betters Quality of Life During Chemoradiotherapy
August 2nd 2023Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.